Medivet - Future State, page-15

Some good points groberts. I can definitely see your profit projections panning out, especially if they manage to secure any additional new OEM deals (500k+) whilst maintaining their margins. The recent resurgence in the core business and reasonably positive quarterly hinting to an improved 2HY, outlook leads me to believe MLA could well be on track.


"the TUTA T-site Needle-free injection port, which went from inception to market in under four months. The new product filled a gap identified in the market by the MLA team, and is now widely distributed."

"Due to the restructure and streamlining of the MediVet subsidiary and the one-off costs associated with these initiatives, MLA experienced negative operating cashflow of $302,000 for the quarter. This figure is in line with expectations, and the Company expects to see the benefits of these initiatives during the second half of FY2015."

"MLA has completed the first half of financial year 2015 with a pleasing revenue result that demonstrates solid organic sales and growth."

"MLA rolled out these initiatives in the second quarter, commencing with the appointment of experienced veterinary sales professionals both in the US and Australia. The purpose of this is to achieve greater acceptance, understanding and uptake of the MediVet subsidiary’s proprietary regenerative stem cell treatments by veterinarians."